CTLM Technology to be Highlighted at Molecular Imaging Conference
FORT LAUDERDALE, Fla., Jan. 29 /PRNewswire-FirstCall/ -- Imaging Diagnostic Systems, Inc., (OTC Bulletin Board: IMDS) a pioneer in laser optical breast imaging, is exhibiting at Arab Health 2008, January 28 - 31, 2008, in Dubai, United Arab Emirates. The company is located at stand CD89.
CTLM technology was featured during the Molecular Imaging Conference, one of 17 conferences on specialized areas featured at Arab Health. Professor Eric Milne detailed the principals of imaging the breast with CTLM in his lecture, "Optical Imaging: Computed Tomographic Laser Mammography of the Breast." Observations from one of the Company's Luminary Partner sites were also presented. Professor Paolo Belli from Catholic University, Rome, Italy, discussed his experiences with CTLM in his talk, "Clinical Experience with Computed Tomography Laser Mammography Breast Scanning System."
"The Molecular Imaging Conference at Arab Health 2008 illustrates dramatically how the most advanced technologies have been rapidly disseminated throughout the world. Heavy emphasis is being placed on the need to image function rather than form, which is where CT Laser Mammography excels," explained Professor Milne. "As part of the Molecular Imaging and PET/CT conference, I presented the methodology and clinical results of CTLM, obtained from 11 of our clinical centers throughout the world. I demonstrated how laser imaging can achieve the same three-dimensional functional images as PET, but without the need for cyclotrons, radioactive injectates, or physicists at a fraction of the cost and time needed for imaging."
More than 50,000 medical professionals are expected to attend Arab Health, the world's largest multi-track healthcare Congress.
About Imaging Diagnostic Systems, Inc.
Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLM(R) system is a breast imaging system that utilizes patented continuous wave laser technology and computer algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CT Laser Mammography (CTLM(R)) is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth.
The FDA has determined that the Company's clinical study is a non- significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States.
For more information, visit our website: http://www.imds.com
As contemplated by the provisions of the Safe Harbor section of the
Private Securities Litigation Reform Act of 1995, this news release may
contain forward-looking statements pertaining to future, anticipated, or
projected plans, performances and developments, as well as other statements
relating to future operations. All such forward-looking statements are
necessarily only estimates or predictions of future results or events and
there can be no assurance that actual results or events will not materially
differ from expectations. Further information on potential factors that
could affect Imaging Diagnostic Systems, Inc., is included in the Company's
filings with the Securities and Exchange Commission. We expressly disclaim
any intent or obligation to update any forward-looking statements.
|SOURCE Imaging Diagnostic Systems, Inc.|
Copyright©2008 PR Newswire.
All rights reserved